Genetic features and efficacy of decitabine-based chemotherapy in elderly patients with acute myeloid leukemia

References

• Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995;45(1):8–30.
   PubMed Web of Science ®Google Scholar
• Khwaja A, Bjorkholm M, Gale RE, et al. Acute myeloid leukaemia. Nat Rev Dis Primers. 2016;2:16010. doi:https://doi.org/10.1038/nrdp.2016.10.
   PubMed Web of Science ®Google Scholar
• Klepin HD. Elderly acute myeloid leukemia: assessing risk. Curr Hematol Malig Rep. 2015;10(2):118–125. doi:https://doi.org/10.1007/s11899-015-0257-2.
   PubMed Web of Science ®Google Scholar
• Eigendorff E, Hochhaus A. Akute leukämien des erwachsenen. Pathologe. 2015;36(5):503–517; quiz 518–9. doi:https://doi.org/10.1007/s00292-015-0087-y.
   PubMedGoogle Scholar
• Webster JA, Pratz KW. Acute myeloid leukemia in the elderly: therapeutic options and choice. Leuk Lymphoma. 2017: 1–14. doi:https://doi.org/10.1080/10428194.2017.1330956.
   Google Scholar
• Hassan C, Afshinnekoo E, Li S, et al. Genetic and epigenetic heterogeneity and the impact on cancer relapse. Exp Hematol. 2017. doi:https://doi.org/10.1016/j.exphem.2017.07.002.
   Google Scholar
• Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia. Blood. 2016;127(1):53–61. doi:https://doi.org/10.1182/blood-2015-08-604520.
   PubMed Web of Science ®Google Scholar
• Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–1089. doi:https://doi.org/10.1056/NEJMoa1112304.
   PubMed Web of Science ®Google Scholar
• Hou HA, Lin CC, Chou WC, et al. Integration of cytogenetic and molecular alterations in risk stratification of 318 patients with de novo non-M3 acute myeloid leukemia. Leukemia. 2014;28(1):50–58. doi:https://doi.org/10.1038/leu.2013.236.
   PubMed Web of Science ®Google Scholar
• Wakita S, Yamaguchi H, Ueki T, et al. Complex molecular genetic abnormalities involving three or more genetic mutations are important prognostic factors for acute myeloid leukemia. Leukemia. 2016;30(3):545–554. doi:https://doi.org/10.1038/leu.2015.288.
   PubMed Web of Science ®Google Scholar
• Ofran Y, Rowe JM. Genetic profiling in acute myeloid leukaemia–where are we and what is its role in patient management. Br J Haematol. 2013;160(3):303–320. doi:https://doi.org/10.1111/bjh.12135.
   PubMed Web of Science ®Google Scholar
• Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424–2433. doi:https://doi.org/10.1056/NEJMoa1005143.
   PubMed Web of Science ®Google Scholar
• Liu WJ, Tan XH, Luo XP, et al. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis. Leuk Lymphoma. 2014;55(12):2691–2698. doi:https://doi.org/10.3109/10428194.2014.893308.
   PubMed Web of Science ®Google Scholar
• Schnittger S, Eder C, Jeromin S, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia. 2013;27(1):82–91. doi:https://doi.org/10.1038/leu.2012.262.
   PubMed Web of Science ®Google Scholar
• Metzeler KH, Walker A, Geyer S, et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia. 2012;26(5):1106–1107. doi:https://doi.org/10.1038/leu.2011.342.
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014;124(17):2705–2712. doi:https://doi.org/10.1182/blood-2014-06-582809.
   PubMed Web of Science ®Google Scholar
• Emadi A, Faramand R, Carter-Cooper B, et al. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. Am J Hematol. 2015;90(5):E77–E79. doi:https://doi.org/10.1002/ajh.23965.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011;25(7):1147–1152. doi:https://doi.org/10.1038/leu.2011.71.
   PubMed Web of Science ®Google Scholar
• Greenblatt SM, Nimer SD. Chromatin modifiers and the promise of epigenetic therapy in acute leukemia. Leukemia. 2014;28(7):1396–1406. doi:https://doi.org/10.1038/leu.2014.94.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Grishina O, Schmoor C, et al. Valproate and retinoic acid in combination with decitabine in elderly nonfit patients with acute myeloid leukemia: results of a multicenter, randomized, 2×2, phase II trial. Am. J Clin Oncol. 2019: JCO1901053. doi:https://doi.org/10.1200/JCO.19.01053.
   Google Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. 2014;28(1):78–87. doi:https://doi.org/10.1038/leu.2013.269.
   PubMed Web of Science ®Google Scholar
• Hiller JK, Schmoor C, Gaidzik VI, et al. Evaluating the impact of genetic and epigenetic aberrations on survival and response in acute myeloid leukemia patients receiving epigenetic therapy. Ann Hematol. 2017;96(4):559–565. doi:https://doi.org/10.1007/s00277-016-2912-7.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:https://doi.org/10.1182/blood-2016-03-643544.
   PubMed Web of Science ®Google Scholar
• Kiyoi H, Naoe T, Nakano Y, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074–3080.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood. 2015;125(9):1367–1376. doi:https://doi.org/10.1182/blood-2014-11-610543.
   PubMed Web of Science ®Google Scholar
• Hou HA, Liu CY, Kuo YY, et al. Splicing factor mutations predict poor prognosis in patients with de novo acute myeloid leukemia. Oncotarget. 2016;7(8):9084–9101. doi:https://doi.org/10.18632/oncotarget.7000.
   PubMedGoogle Scholar
• O'Donnell MR, Tallman MS, Abboud CN, et al. Acute myeloid leukemia, version 3.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2017;15(7):926–957. doi:https://doi.org/10.6004/jnccn.2017.0116.
   PubMed Web of Science ®Google Scholar
• Krug U, Gale RP, Berdel WE, et al. Therapy of older persons with acute myeloid leukaemia. Leuk Res. 2017;60:1–10. doi:https://doi.org/10.1016/j.leukres.2017.05.020.
   PubMed Web of Science ®Google Scholar
• Kiyoi H. Overview: a new era of cancer genome in myeloid malignancies. Oncology. 2015;89(Suppl 1):1–3. doi:https://doi.org/10.1159/000431054.
   PubMedGoogle Scholar
• Burnett A, Wetzler M, Lowenberg B. Therapeutic advances in acute myeloid leukemia. J Clin Oncol. 2011;29(5):487–494. doi:https://doi.org/10.1200/JCO.2010.30.1820.
   PubMed Web of Science ®Google Scholar
• Tallman MS. New strategies for the treatment of acute myeloid leukemia including antibodies and other novel agents. Hematology Am Soc Hematol Educ Program. 2005;2005(1):143–150. doi:https://doi.org/10.1182/asheducation-2005.1.143.
   Google Scholar
• Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the eastern cooperative oncology group. Blood. 2004;103(2):479–485. doi:https://doi.org/10.1182/blood-2003-05-1686.
   PubMed Web of Science ®Google Scholar
• Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood. 2007;109(12):5129–5135. doi:https://doi.org/10.1182/blood-2007-02-069666.
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7(9):1268–1274. doi:https://doi.org/10.1200/JCO.1989.7.9.1268.
   PubMed Web of Science ®Google Scholar
• Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109(6):1114–1124. doi:https://doi.org/10.1002/cncr.22496.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–474. doi:https://doi.org/10.1182/blood-2009-07-235358.
   PubMed Web of Science ®Google Scholar
• Grimwade D, Hills RK, Moorman AV, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–365. doi:https://doi.org/10.1182/blood-2009-11-254441.
   PubMed Web of Science ®Google Scholar
• Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59(15):3730–3740.
   PubMed Web of Science ®Google Scholar
• Toyota M, Kopecky KJ, Toyota MO, et al. Methylation profiling in acute myeloid leukemia. Blood. 2001;97(9):2823–2829.
   PubMed Web of Science ®Google Scholar
• Qin T, Youssef EM, Jelinek J, et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res. 2007;13(14):4225–4232. doi:https://doi.org/10.1158/1078-0432.CCR-06-2762.
   PubMed Web of Science ®Google Scholar
• Cruijsen M, Lubbert M, Wijermans P, et al. Clinical results of hypomethylating agents in AML treatment. J Clin Med. 2015;4(1):1–17. doi:https://doi.org/10.3390/jcm4010001.
   Web of Science ®Google Scholar
• Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol. 2010;28(4):605–613. doi:https://doi.org/10.1200/JCO.2009.23.4781.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677. doi:https://doi.org/10.1200/JCO.2011.38.9429.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Suciu S, Baila L, et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol. 2011;29(15):1987–1996. doi:https://doi.org/10.1200/JCO.2010.30.9245.
   PubMed Web of Science ®Google Scholar
• Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA. 2010;107(16):7473–7478. doi:https://doi.org/10.1073/pnas.1002650107.
   PubMed Web of Science ®Google Scholar
• Bhatla T, Wang J, Morrison DJ, et al. Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia. Blood. 2012;119(22):5201–5210. doi:https://doi.org/10.1182/blood-2012-01-401687.
   PubMed Web of Science ®Google Scholar
• Li J, Chen Y, Zhu Y, et al. Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia. Oncotarget. 2015;6(8):6448–6458. doi:https://doi.org/10.18632/oncotarget.3361.
   PubMedGoogle Scholar
• Scandura JM, Roboz GJ, Moh M, et al. Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood. 2011;118(6):1472–1480. doi:https://doi.org/10.1182/blood-2010-11-320093.
   PubMed Web of Science ®Google Scholar
• Lubbert M, Ruter BH, Claus R, et al. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica. 2012;97(3):393–401. doi:https://doi.org/10.3324/haematol.2011.048231.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood. 2012;120(24):4840–4845. doi:https://doi.org/10.1182/blood-2012-06-436055.
   PubMed Web of Science ®Google Scholar
• Mayer J, Arthur C, Delaunay J, et al. Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics. BMC Cancer. 2014;14:69. doi:https://doi.org/10.1186/1471-2407-14-69.
   PubMed Web of Science ®Google Scholar
• Xu Q, Li Y, Jing Y, et al. Epigenetic modifier gene mutations-positive AML patients with intermediate-risk karyotypes benefit from decitabine with CAG regimen. Int J Cancer. 2020;146(5):1457–1467.
   PubMed Web of Science ®Google Scholar
• Wang B, Liu Y, Hou G, et al. Mutational spectrum and risk stratification of intermediate-risk acute myeloid leukemia patients based on next-generation sequencing. Oncotarget. 2016;7(22):32065–32078. doi:https://doi.org/10.18632/oncotarget.7028.
   PubMedGoogle Scholar
• Thomas X, Le Jeune C. Treatment of elderly patients with acute myeloid leukemia. Curr Treat Options Oncol. 2017;18(1):2. doi:https://doi.org/10.1007/s11864-017-0445-5.
   PubMed Web of Science ®Google Scholar
• Chang E, Ganguly S, Rajkhowa T, et al. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells. Leukemia. 2016;30(5):1025–1032. doi:https://doi.org/10.1038/leu.2015.346.
   PubMed Web of Science ®Google Scholar
• Yanada M, Naoe T. Acute myeloid leukemia in older adults. Int J Hematol. 2012;96(2):186–193. doi:https://doi.org/10.1007/s12185-012-1137-3.
   PubMed Web of Science ®Google Scholar
• Shallis RM, Boddu PC, Bewersdorf JP, et al. The golden age for patients in their golden years: The progressive upheaval of age and the treatment of newly-diagnosed acute myeloid leukemia. Blood Rev. 2019: 100639. doi:https://doi.org/10.1016/j.blre.2019.100639.
   PubMed Web of Science ®Google Scholar